Drug Trial Radar · NCT07154745
A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently
Last checked: Nov 20, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
35
Planned (sponsor's estimate)
Start
Jun 11, 2026
Primary completion
Jan 18, 2030
Study completion Dec 4, 2031
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Sep 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching a treatment combination with two experimental drugs called pozelimab and cemdisiran referred to as "study drugs". Researchers are looking for a better way to treat Paroxysmal Nocturnal Hemoglobinuria (PNH). The aim of the study is to see how well the pozelimab and cemdisiran combination works to lower hemolysis in participants whose PNH has been not well controlled even after taking other complement component 5 (C5) inhibitors, eculizumab/eculizumab biosimilar, ravulizumab or crovalimab. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs? * How much of the study drugs are in the blood at different times? * Whether the body makes antibodies against the study drug (which could make the study drugs not work as well or could lead to side effects)
Conditions
- Paroxysmal Nocturnal Hemoglobinuria
Interventions
PozelimabDrug
Administered per the protocol
CemdisiranDrug
Administered per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change in Lactate Dehydrogenase (LDH) during TPTime frame: From baseline to week 28
Locations
20 sites in 7 countries. Site status is shown where the registry gives one.
Hospital Santa Marcelina
São Paulo, Brazil · Recruiting
Hospital das Clinicas da FMRP USP
Ribeirão Preto, São Paulo, Brazil · Recruiting
Faculdade de Medicina do ABC
Santo André, São Paulo, Brazil · Recruiting
CISSS-CA
Lévis, Quebec, Canada · Recruiting
SC Hematology, AOU Città della Salute e della Scienza di Torino
Torino, Italy · Recruiting
Universita Cattolica del Sacro Cuore - Policlinico Universitario A. Gemelli
Rome, Lazio, Italy · Recruiting
AOU Careggi
Florence, Tuscany, Italy · Recruiting
In-Vivo Sp. z o.o.
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland · Recruiting
Seoul National University Hospital
Seoul, South Korea · Recruiting
Severance Hospital
Seoul, South Korea · Recruiting
Seoul St. Mary's Hospital - The Catholic University of Korea
Seoul, South Korea · Recruiting
Ewha Womans University Mokdong Hospital
Seoul, South Korea · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
Institut Catala d'Oncologia
Barcelona, Spain · Recruiting
Hospital San Pedro de Alcantara
Cáceres, Spain · Recruiting
Hospital General JM Morales Meseguer
Murcia, Spain · Recruiting
Hospital Universitario de Salamanca
Salamanca, Spain · Recruiting
Hospital Universitario Basurto
Bilbao, Vizcaya, Spain · Recruiting
Istanbul University Istanbul Faculty of Medicine
Istanbul, Turkey (Türkiye) · Recruiting
Ege University
Izmir, Turkey (Türkiye) · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.